Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Corporate Presentation October 2024

Key points covered in the presentation include N4 Pharma's strategic focus on two key lead programs: N4 101 for Irritable Bowel Disease (“IBD”) and ECP 105 for post-surgical scarring prevention, utilising the Company’s proprietary delivery technologies, Nuvec® and LipTide™. The Company’s aim is to advance preclinical studies and prepare for a Clinical Trial Authorisation (“CTA”) / Investigational New Drug (“IND”) filing in the coming years, while also pursuing licensing and platform collaboration opportunities.

Investors can watch the presentation accompanied by a video update from CEO Nigel Theobald here.

Investors are invited to submit their questions through the N4 Pharma Investor Hub below. The team will respond to questions in due course.

N4 Pharma Corporate Presentation - October 2024